Trials / Completed
CompletedNCT00879684
Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors
A Phase 1, Multicenter, Open-label, Dose-escalation, Safety, Pharmacokinetic, And Pharmacodynamic Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CVX-060 | Weekly, intravenous dose |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2011-04-01
- Completion
- 2011-04-01
- First posted
- 2009-04-10
- Last updated
- 2015-01-26
- Results posted
- 2015-01-26
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00879684. Inclusion in this directory is not an endorsement.